Phentermine and diethylpropion are central stimulants; they are not recommended for the treatment of obesity. Phentermine has been associated with a risk of pulmonary hypertension.

Sibutramine, dexfenfluramine, and fenfluramine have been withdrawn because the benefit of treatment does not outweigh the risk of serious adverse effects.